Nektar Therapeutics (NKTR) — 10-Q Filings

10-Q Filings (6)

• Nektar's Revenue Halves Amid Product Sales Halt, Net Loss Widens — Nov 7, 2025 Risk: high
  NEKTAR THERAPEUTICS reported a significant decline in total revenue for the nine months ended September 30, 2025, dropping to $33.425 million from $69.252 milli
• Nektar's Q2 Loss Widens Amid Revenue Dip, Raises $85M in Offerings — Aug 8, 2025 Risk: high
  NEKTAR THERAPEUTICS reported a net loss of $59.5 million for the quarter ended June 30, 2025, a significant increase from the $48.3 million net loss in the prio
• Nektar Therapeutics Files Q1 2025 10-Q — May 9, 2025 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key agreements mentio
• Nektar Therapeutics Files Q3 2024 10-Q — Nov 8, 2024 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quar
• Nektar Therapeutics Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter.
• Nektar Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: medium
  NEKTAR THERAPEUTICS (NKTR) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Nektar Therapeutics filed a 10-Q report for the period ending March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX